Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

Jan Harder(Hegau-Bodensee-Klinikum Singen), Michael Geißler(Klinikum Esslingen), Gabriele Ihorst, Christoph Röcken(University Hospital Schleswig-Holstein), Volker Heinemann(LMU Klinikum), Stefan Boeck(German Cancer Research Center), Markus Moehler(Johannes Gutenberg University Mainz), Michael Bitzer(University Children's Hospital Tübingen), Peter Buechler(Heidelberg University), Claudia Schmoor(University Medical Center Freiburg), Esther Endlicher(University Hospital Regensburg), A. Reinacher-Schick(Universitätsklinikum Knappschaftskrankenhaus Bochum), Ralf‐Dieter Hofheinz(University of Mannheim), Günter Kloeppel(Christian-Albrechts-Universität zu Kiel)
British Journal of Cancer
February 28, 2012
10.1038/bjc.2012.18
Cited by 184

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k